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Abstract
Background: The disorder of lipid metabolism and genetic predisposition are major risk factors for coronary artery
disease (CAD). Variants in the apolipoprotein A1 (APOA1) gene play an important role in the regulation of lipids. The
objective of the present study was to investigate the effect of two polymorphisms (-75 G/A and +83 C/T) of APOA1
on lipid profiles and the risk of CAD.
Methods: A total number of 300 subjects with CAD and 300 age and sex matched healthy controls were
enrolled for the study. Genotyping of the APOA1 was performed by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) combined with gel electrophoresis, and then confirmed by direct
sequencing.
Results: The frequencies of APOA1 -75 AA genotype [odds ratio (OR) =0.50, 95 % confidence interval (CI) = 0.28,
0.88; P = 0.02] and APOA1 -75 A allele (OR =0.76, 95 % CI = 0.59, 0.98; P = 0.04) were significantly lower in CAD
than in controls. The APOA1 -75 A allele was significantly associated with increasing serum concentrations of
ApoA1 and high-density lipoprotein cholesterol (HDL-C) (P < 0.001).
Conclusions: The individuals with the APOA1 -75 A allele were likely to have a lower risk of CAD as a result of
its effect on higher serum concentrations of ApoA1 and HDL-C.
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Background
Coronary artery disease (CAD) is the leading cause of
mortality and morbidity in the world [1]. Although the
precise mechanisms responsible for the onset of CAD
are still unknown, it is a multifactorial disease, which is
influenced by interacting endogenous and exogenous
factors [2, 3]. The major risk factors of CAD are age,
stress, hypertension, diabetes mellitus, hyperlipidemia,
smoking, high alcohol consumption, family history of
CAD and obesity [4–8]. The disorder of lipid metabol-
ism and genetic predisposition are major risk factors for
CAD [9–11]. It has been estimated that genetic risk fac-
tors explain approximately 20 %-60 % of CAD cases
[12]. Some genes have been investigated for their in-
volvement in the development of CAD [13, 14].
Apolipoprotein A1 (apoA1) is the major apolipopro-
tein constituent of the high-density lipoprotein (HDL)
and is involved in reverse cholesterol transport [15].
Up to now, several single-nucleotide polymorphisms
(SNPs) have been identified in the APOA1 gene located
on the long arm of chromosome 11 [16]. A common
G-to-A transition located -75 base pairs (bp) upstream
from the transcription start site of the APOA1 gene
has been studied extensively [17]. Another polymorph-
ism site was identified in the first intron of the APOA1
gene that involves transition of C-to-T at +83 bp that
has also been shown to affect HDL and apoA1 levels
[18, 19].
Although three case-control studies have investigated
the association between APOA1 polymorphisms (-75 G/A
and +83 C/T) and the risk of CAD, these studies have
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reported conflicting results [20–22]. The objective of the
present study was to investigate the effect of two polymor-
phisms (-75 G/A and +83 C/T) of APOA1 on lipid profiles
and the risk of CAD in a Chinese population.
Methods
Study population
A total number of 300 subjects with CAD and 300 age
and sex matched healthy controls were enrolled for
the study between July 2011 and June 2014 in the Sec-
ond Clinical Medical College of Jinan University,
China. CAD cases were defined as those having severe
angiostenosis (>50 %) in at least one major coronary
artery determined by angiography based on WHO cri-
teria. CAD cases were selected randomly from patients
admitted to the hospital and who fulfilled the inclu-
sion criteria. The control group was composed of age
and sex matched healthy subjects who had undergone
a coronary angiography in the same recruitment
period as the CAD patients, with normal ECG, nega-
tive stress test, without family history of CAD or other
cardiovascular diseases or angiographic evidence of
CAD. The study was approved by the Institutional
Ethical Committee of the Second Clinical Medical
College of Jinan University. A signed informed con-
sent was obtained from all participants in the study.
Venous blood was collected in evacuated tubes after
an overnight fast of 12 to 14 h.
Biochemical analysis
Serum total cholesterol (TC), triglycerides (TG), high-
density lipoprotein cholesterol (HDL-C) were measured
by the clinical chemistry department using commercial
kits following the manufacturer instructions. Serum low-
density lipoprotein cholesterol (LDL-C) and very-low-
density lipoprotein cholesterol (VLDL-C) were calculated
using the Friedwald’s formula. The immunoturbidimetric
assay was used to quantify the plasma concentrations of
ApoA1 and ApoB.
DNA extraction and genotyping
Total genomic DNA was isolated from peripheral blood
leukocytes by the commercially available Qiagen kit
(QIAGEN Inc., Valencia, CA, USA). Polymerase chain reac-
tion restriction fragment length polymorphism (PCR-RFLP)
assay was performed to assess the APOA1 gene polymor-
phisms. Based on the GenBank reference sequence, the
PCR primer pair used as follows: forward: 5ʹ-AGG GAC
AGA GCT GAT CCT TGA ACT CTT AAG-3ʹ, and re-
verse: 5ʹ-TTA GGG GAC ACC TAG CCC TCA GGA
AGA GCA-3ʹ. The amplified PCR products were digested
with 10 units of the restriction endonuclease enzyme MspI
overnight. The digested fragments were resolved on a 3 %
agarose gel and stained with ethidium bromide for
visualization under UV light. The presence of theMspI re-
striction stie at -75 bp (G allele) and at +83 bp (C allele) in
the 433 bp product resulted in four fragments of 45, 66,
113 and 209 bp. The absence of the restriction site at
-75 bp (A allele) resulted in three fragments of 45, 179
and 209 bp. The absence of the restriction site at +83 bp
(T allele) created a larger fragment of 254 bp instead of
two fragments of 45 and 209 bp. For quality control, we
performed double sampling PCR-RFLP in more than 10 %
of the samples and found no differences, and then con-
firmed by direct sequencing.
Table 1 Distribution of the various phenotypic variables in cases and controls
CAD (n = 300) Controls (n = 300) P
Age (years) 56.7 ± 9.9 56.1 ± 9.7 0.45
Sex (Male/Female) 238/62 231/69 0.49
Smoking status (Ever/Never) 84/216 46/254 <0.001
Diabetes (Positive/Negative) 74/226 42/258 0.001
Hypertension (Positive/Negative) 163/137 144/156 0.12
Obesity (Positive/Negative) 87/213 51/249 0.001
Hyperlipidemia (Positive/Negative) 93/207 49/251 <0.001
TG (mg/dL) 192.1 ± 86.7 167.5 ± 77.4 <0.001
TC (mg/dL) 198.7 ± 58.4 185.3 ± 50.1 0.003
HDL-C (mg/dL) 33.7 ± 11.6 38.9 ± 12.9 <0.001
LDL-C (mg/dL) 126.6 ± 37.4 112.9 ± 33.8 <0.001
VLDL-C (mg/dL) 38.4 ± 21.5 33.5 ± 20.3 0.004
ApoA1 (mg/dL) 123.5 ± 22.3 131.9 ± 23.5 <0.001
ApoB (mg/dL) 91.4 ± 27.3 90.6 ± 26.7 0.72
Abbreviations: CAD, coronary artery disease; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; Apo, apolipoprotein
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Statistical analysis
Statistical analyses were performed by SPSS software for
Windows (SPSS 11.0 SPSS Inc., Chicago, IL). Allele fre-
quencies were calculated by the gene counting method.
Differences between continuous variables were assessed
by Student’s t test, while those between categorical
variables were evaluated using x2 test. The existence of
differences in genotypic frequencies between groups was
assessed by means of x2 test. The odds ratio (OR) and
95 % confidence intervals (CI) were also calculated. P <
0.05 was required for statistical significance.
Results
Characteristics of participants
Distribution of the various phenotypic variables in cases
and controls were shown in Table 1. No significant
differences were found between the CAD cases and con-
trols in age, sex, hypertension and ApoB (Table 1). HDL-
C and ApoA1 were significantly decreased (P < 0.001), but
TG (P < 0.001), TC (P = 0.003), LDL-C (P < 0.001) and
VLDL-C (P = 0.004) levels were significantly increased in
patients as compared to controls. Multiple logistic regres-
sion analysis of known predictors of CAD confirmed the
independent role of smoking status (P < 0.001), diabetes
(P = 0.001), obesity (P = 0.001), hyperlipidemia (P < 0.001)
and ApoA1 (P < 0.001) as risk factors of CAD (Table 1).
APOA1 -75 G/A polymorphisms, lipids and CAD
The frequencies of APOA1 -75 AA genotype (OR = 0.50,
95 % CI = 0.28, 0.88; P = 0.02) and APOA1 -75 A allele
(OR =0.76, 95 % CI = 0.59, 0.98; P = 0.04) were signifi-
cantly lower in CAD than in controls (Table 2). The
APOA1 -75 A allele was significantly associated with in-
creasing serum concentrations of ApoA1 and high-density
lipoprotein cholesterol (HDL-C) (P < 0.001) (Table 3).
APOA1 + 83 C/T polymorphisms, lipids and CAD
No association was found between APOA1 + 83 C/T
polymorphisms and risk of CAD (Table 2).
Discussion
Many studies have been conducted to test the association
of SNPs and CAD. A meta-analysis of thirteen case-
control studies suggested that thrombomodulin -33G/A
and Ala455Val polymorphisms were risk factors for CAD
[23, 24]. A meta-analysis of 72 studies including 23,557
cases and 21,526 controls suggested that plasminogen ac-
tivator inhibitor-1 4G/5G polymorphism was a risk factor
for CAD [25]. A meta-analysis of 10,617 cases and 8,302
controls from 37 studies revealed that endothelial nitric
oxide synthase 4b/a polymorphisms could be a risk factor
for developing CAD, particularly in African populations
and population-based subgroups [26]. A meta-analysis of
21 eligible literatures confirmed a protective effect of
C242T polymorphism of CYBA gene on CAD in Asian
population and indicated that A640G polymorphism of
CYBA gene was significantly associated with decreased
Table 2 Genotype and allele frequencies of APOA1 gene
polymorphisms (-75 G/A and +83 C/T) among CAD cases and
healthy controls
Cases (n = 300) Controls (n = 300) OR (95%CI) P
Genotype
GG 175(58.3) 161(53.7) 1.00(Reference)
GA 104(34.7) 100(33.3) 0.96(0.68,1.36) 0.80
AA 21(7.0) 39(13.0) 0.50(0.28,0.88) 0.02
CC 221(73.7) 230(76.7) 1.00(Reference)
CT 54(18.0) 39(13.0) 1.44(0.92,2.26) 0.11
TT 25(8.3) 31(10.3) 0.84(0.48,1.47) 0.54
Allele
G 454(75.7) 422(70.3) 1.00(Reference)
A 146(24.3) 178(29.7) 0.76(0.59,0.98) 0.04
C 496(82.7) 499(83.2) 1.00(Reference)
T 104(17.3) 101(16.8) 1.04(0.77,1.40) 0.82
APOA1, apolipoprotein A1; CAD, coronary artery disease; OR, odds ratio;
CI, confidence interval
Table 3 Lipid profiles of CAD cases and controls according to APOA1 -75 G/A polymorphisms
CAD P value Controls P value
GG GA AA GG GA AA
TG (mg/dL) 187.1 ± 79.3 198.9 ± 92.5 175.5 ± 86.2 0.72 160.5 ± 57.3 176.1 ± 62.4 156.9 ± 59.8 0.68
TC (mg/dL) 192.4 ± 55.7 206.4 ± 59.4 203.3 ± 56.8 0.44 178.9 ± 48.7 194.8 ± 53.6 191.4 ± 50.2 0.39
HDL-C (mg/dL) 30.4 ± 10.6 36.8 ± 11.9 41.5 ± 12.7 <0.001 37.1 ± 12.0 41.2 ± 13.6 46.8 ± 14.5 <0.001
LDL-C (mg/dL) 124.6 ± 36.9 129.8 ± 40.1 126.7 ± 38.2 0.87 109.7 ± 30.5 118.4 ± 36.5 113.2 ± 33.7 0.69
VLDL-C (mg/dL) 37.4 ± 12.4 39.8 ± 19.7 35.1 ± 10.6 0.31 32.1 ± 17.6 35.2 ± 18.4 31.4 ± 16.2 0.42
ApoA1 (mg/dL) 114.5 ± 20.7 127.6 ± 22.5 138.9 ± 24.1 <0.001 124.4 ± 23.5 135.7 ± 24.3 144.7 ± 25.8 <0.001
ApoB (mg/dL) 86.7 ± 25.4 97.6 ± 29.5 90.7 ± 26.9 0.63 88.1 ± 25.8 93.6 ± 27.5 89.5 ± 26.7 0.74
CAD, coronary artery disease; APOA1, apolipoprotein A1; OR, odds ratio; CI, confidence interval; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; Apo, apolipoprotein
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risk of CAD [27]. A meta-analysis of ten studies suggested
there was an increase in the risk of CAD conferred by the
E-selectin Ser128Arg polymorphism and the P-selectin
thr715Pro polymorphism may be a protective factor of
myocardial infarction [28]. A meta-analysis of eighteen
studies with 3,546 cases and 3,852 controls suggested that
the intercellular adhesion molecule-1 K469E polymorph-
ism was a risk factor for CAD [29]. A meta-analysis of
thirty case-control studies suggested that EcoRI and
SpIns/Del polymorphisms of the APO B gene significantly
increased the risk of CAD [30].
The APOA1 gene polymorphisms were also extensively
studied and reported to be associated with other dis-
eases. A hospital-based case-control study found that
APOA1 -75 AA genotype was associated with a higher
acute lung injury (ALI) risk after cardiopulmonary by-
pass (CPB) surgery. Those patients with the APOA1 -75
AA genotype and A allele had higher 30-day mortality of
ALI after CPB surgery [31]. A case-control study found
an association of the APOA1 -75G/A promoter poly-
morphism with cognitive performance in multiple scler-
osis [32]. A prospective case-control study found a
positive association between APOA1 -75 A allele carriers
and breast cancer risk [33]. A pilot study in a north In-
dian population suggested that APOA1 polymorphisms
(-75 G/A and +83 C/T) might be susceptibility to myo-
cardial infarction [19]. A case-control study found the
APOA1 -75 A allele was associated with an increased
risk for Alzheimer's disease [34]. A Brazilian elderly
cohort showed that APOA1 polymorphisms (-75 G/A
and +83 C/T) could be as risk factors for hypertension
and obesity [35]. A case-control study suggested that
the APOA1 -75 G/A polymorphism was associated
with gallstone disease and shows sex-specific differ-
ences [36].
Although our results revealed that the individuals with
the APOA1 -75 A allele were likely to have a lower risk
of CAD as a result of its effect on higher serum concen-
trations of ApoA1 and HDL-C, the exact mechanism is
still unclear. However, the results have been inconsistent
and inconclusive, with few studies reporting either no
association or negative association between APOA1 -75
A allele and plasma lipids [37–39]. Our study was con-
sistent with some other studies [17, 40–44].
Several shortcomings of the present study should be
discussed. Firstly, CAD, a multifactorial disease, is influ-
enced by interacting endogenous and exogenous factors,
which were not explored in the present study. Secondly,
the subjects in this research are only from Han Chinese
ethnic group. It would be interesting to conduct similar
studies in different populations for comparison.
Thirdly, about 50 % cases took statins by which
lipid levels are affected. We have adjusted for medi-
cine use in this analysis, but no information could
be received on the baseline lipid levels of these
cases. Finally, the potential selection bias cannot be
avoidable, because this is a hospital based case con-
trol study and the subjects may not be representa-
tive of the general population.
Conclusions
In conclusion, our results indicated that the individuals
with the APOA1 -75 A allele were likely to have a lower
risk of CAD as a result of its effect on higher serum con-
centrations of ApoA1 and HDL-C. Additional studies
are needed to confirm this finding.
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